$1.50
-0.005[-0.33%]
At close: Apr 18
$1.50
0[0.00%]
After Hours: 4:09PM EDT
Unity Biotechnology
(NASDAQ:UBX)Unity Biotechnology Stock (NASDAQ:UBX), Analyst Ratings, Price Targets, Predictions
Unity Biotechnology Inc has a consensus price target of $6.38, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Wedbush, and HC Wainwright & Co. on April 16, 2024, November 16, 2023, and November 14, 2023. With an average price target of $6 between HC Wainwright & Co., Wedbush, and HC Wainwright & Co., there's an implied 300.00% upside for Unity Biotechnology Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
HC Wainwright & Co.
Roth MKM
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Unity Biotechnology
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | UBX | Buy Now | Unity Biotechnology | $1.50 | 433.33% | HC Wainwright & Co. | Andrew Fein | $10 → $8 | Maintains | Buy | Get Alert |
| 11/16/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | — | Wedbush | Andreas Argyrides | — | Upgrade | Neutral → Outperform | Get Alert |
| 11/14/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 33.33% | Wedbush | Andreas Argyrides | $3 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 05/31/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | Roth MKM | Dylan Dupuis | → $10 | Initiates | → Buy | Get Alert |
| 05/26/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 300% | Citigroup | Yigal Nochomovitz | $5 → $6 | Maintains | Buy | Get Alert |
| 05/10/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 100% | Wedbush | Andreas Argyrides | $5 → $3 | Maintains | Outperform | Get Alert |
| 03/28/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 300% | Mizuho | Salim Syed | $12 → $6 | Maintains | Buy | Get Alert |
| 03/28/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 233.33% | Wedbush | Andreas Argyrides | $35 → $5 | Maintains | Outperform | Get Alert |
| 03/28/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 233.33% | Citigroup | Yigal Nochomovitz | $15 → $5 | Maintains | Buy | Get Alert |
| 03/16/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 2233.33% | Wedbush | Andreas Argyrides | → $35 | Reiterates | → Outperform | Get Alert |
| 03/16/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Andrew Fein | → $10 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Andrew Fein | → $10 | Maintains | Buy | Get Alert |
| 11/16/2022 | UBX | Buy Now | Unity Biotechnology | $1.50 | 700% | Mizuho | Salim Syed | $80 → $12 | Maintains | Buy | Get Alert |
| 11/09/2022 | UBX | Buy Now | Unity Biotechnology | $1.50 | 566.67% | HC Wainwright & Co. | Andrew Fein | $12 → $10 | Maintains | Buy | Get Alert |
| 11/02/2022 | UBX | Buy Now | Unity Biotechnology | $1.50 | 2300% | Wedbush | Andreas Argyrides | $4 → $36 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Unity Biotechnology (UBX)?
The latest price target for Unity Biotechnology (NASDAQ: UBX) was reported by HC Wainwright & Co. on April 16, 2024. The analyst firm set a price target for $8.00 expecting UBX to rise to within 12 months (a possible 433.33% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Unity Biotechnology (UBX)?
The latest analyst rating for Unity Biotechnology (NASDAQ: UBX) was provided by HC Wainwright & Co., and Unity Biotechnology maintained their buy rating.
When was the last upgrade for Unity Biotechnology (UBX)?
The last upgrade for Unity Biotechnology Inc happened on November 16, 2023 when Wedbush raised their price target to N/A. Wedbush previously had a neutral for Unity Biotechnology Inc.
When was the last downgrade for Unity Biotechnology (UBX)?
The last downgrade for Unity Biotechnology Inc happened on June 26, 2023 when Wedbush changed their price target from $3 to $2 for Unity Biotechnology Inc.
When is the next analyst rating going to be posted or updated for Unity Biotechnology (UBX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Unity Biotechnology (UBX) correct?
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a maintained with a price target of $10.00 to $8.00. The current price Unity Biotechnology (UBX) is trading at is $1.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.